Rallybio Corp
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
RLYB$15.76+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| FOR THE YEAR ENDEDDECEMBER 31, | ||
|---|---|---|
| (in thousands) | 2025 | 2024 |
| Cash Flows Used in Operating Activities: | ||
| Net loss | $(8,978) | $(57,775) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 92 | 131 |
| Net accretion of discounts/premiums on debt securities | (573) | (1,612) |
| Share-based compensation | 5,314 | 7,993 |
| Gain on sale of joint venture | (22,350) | — |
| Loss on investment in joint venture | 874 | 2,239 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses, operating right-of-use assets and other current assets | (2,043) | 2,724 |
| Accounts payable | (152) | (698) |
| Accrued expenses and operating lease liabilities | (1,149) | (3,344) |
| Deferred revenue | (848) | 1,060 |
| Net cash used in operating activities | $(29,813) | $(49,282) |
| Cash Flows Provided by Investing Activities: | ||
| Purchases of marketable securities | (17,697) | (48,933) |
| Proceeds from maturities of marketable securities | 46,465 | 84,425 |
| Proceeds from sale of common stock received from sale of joint venture | 20,000 | — |
| Investment in joint venture | (1,500) | (2,000) |
| Net cash provided by investing activities | $47,268 | $33,492 |
| Cash Flows Provided by Financing Activities: | ||
| Proceeds from the issuance of common stock from a securities purchase agreement | — | 5,405 |
| Proceeds from the issuance of common stock under the stock purchase plan | 16 | 62 |
| Payments of offering costs | — | (268) |
| Net cash provided by financing activities | $16 | $5,199 |
| Net increase (decrease) in cash and cash equivalents | 17,471 | (10,591) |
| Cash and cash equivalents—beginning of year | 13,903 | 24,494 |
| Cash and cash equivalents—end of year | $31,374 | $13,903 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.